IVB102

**IVB102** is an AAV-based gene therapy developed for the treatment of **X-linked retinoschisis (XLRS)**, a rare inherited retinal degenerative disorder primarily affecting young males and caused by mutations in the RS1 gene. IVB102 is designed to deliver a functional RS1 gene to retinal cells to restore normal retinoschisin protein expression and improve retinal integrity and function. It is administered via intravitreal injection and is based on a novel AAV vector platform independently developed by the company. IVB102 has received FDA Rare Pediatric Disease Designation for XLRS and is currently in early-phase (Phase 1) clinical trials[1][2][3][4][6][7][10].